Input tax credit conditions remain constitutionally valid, with eligible recipient claims considered under GST circulars and retrospective filing dead...
Bogus donation receipts justified commission income assessment and defeated political-party tax exemption for inaccurate accounts and reporting failur...
Pure reimbursement without income element escapes tax withholding, while delayed withholding and unsupported provisions face deferred or renewed scrut...
Public benefit requirement defeats charitable registration where residents' association services are reciprocal, member-only facilities governed by mu...
Exempt-income expenditure disallowance is confined to investments that actually generated exempt income, while supported business expenses remain dedu...
This notification amends the export policy condition for cough syrup under Chapter 30 of Schedule-II (Export Policy) of ITC (HS) 2022. The existing policy mandated testing and obtaining a Certificate of Analysis from specified laboratories for exporting cough syrup. The revised policy introduces exemptions from this testing requirement in certain situations: (i) If the cough syrup is exported to USA, UK, Canada, EU, Japan, Australia, Singapore, South Korea, and Switzerland, and the manufacturing plant/section is approved by the regulatory agencies of these countries, testing is not required. (ii) If the cough syrup is manufactured in a plant/section approved by the regulatory agencies of the above-mentioned countries for any product, it can be exported to any country without testing. The effect is to waive mandatory testing for cough syrup exports in line with required GMP standards when exported to or manufactured in facilities approved by specified countries' regulatory agencies.
This notification amends the export policy condition for cough syrup under Chapter 30 of Schedule-II (Export Policy) of ITC (HS) 2022. The existing policy mandated testing and obtaining a Certificate of Analysis from specified laboratories for exporting cough syrup. The revised policy introduces exemptions from this testing requirement in certain situations: (i) If the cough syrup is exported to USA, UK, Canada, EU, Japan, Australia, Singapore, South Korea, and Switzerland, and the manufacturing plant/section is approved by the regulatory agencies of these countries, testing is not required. (ii) If the cough syrup is manufactured in a plant/section approved by the regulatory agencies of the above-mentioned countries for any product, it can be exported to any country without testing. The effect is to waive mandatory testing for cough syrup exports in line with required GMP standards when exported to or manufactured in facilities approved by specified countries' regulatory agencies.
Note: It is a system-generated summary and is for quick reference only.
TaxTMI 
of 4782
Join Channel
TaxTMI 
